ClinicalTrials.gg
RecruitingNCT05303805Updated Oct 27, 2026

Topical Sevoflurane for Treatment of Chronic Leg Ulcers

A Phase 4 interventional study of Sevoflurane and Cyteal in Leg Ulcer, sponsored by Charles University, Czech Republic. Recruiting at 1 site in Czechia. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-27.

Sponsored by Charles University, Czech Republic · Phase 4, Interventional, and Treatment

How we know

From the registry’s dates

  • Started May 2022; still recruiting 4 years 6 months later.
Updated Oct 27, 2026Primary completion movedStudy completion moved+2 moreGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
50
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Patients with painful non-healing leg ulcer will be enrolled in the clinical single-blinded randomized study. The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment, the control group will only have a standard rinse solution with Cyteal TM (Pierre Fabre Medicament, France). Further treatment will then be carried out in the standard manner. The duration of the study will be 5 days; if the defect heals earlier, it will be terminated early.

Exclusion criteria: allergy to sevoflurane, inability to understand the questionnaire

Parameters to be monitored will be pain intensity, microbial colonization, appearance and size of the defect

Read the detailed description

A prospective single-blinded randomized study will be conducted in patients of the Dermatovenereology Clinic of the 3rd Medical Faculty of Charles University (3LF UK) and the University Hospital Kralovske Vinohrady (FNKV) with painful non-healing tibial ulcers. Pain intensity on a numerical rating scale (NRS 0-10) must be NRS>4. The envelope method will be used for randomization. To blind patients, therapy will be performed by separating patients with a drape from the treatment area of the body. As sevoflurane has a typical odor, it will only be used in the control group to soak up absorbent material held under the distal pole of the wound without skin contact. In the active treatment group, sevoflurane will be applied at the beginning of the wound treatment at approximately 1 ml/cm2 of the ulcer surface. The standard therapy used in the control group will use only Cyteal TM lavage solution, which contains hexamidine diisetione 100 mg in 100 ml, chlorhexidine digluconate 20% solution 100 mg and chlorocresol 300 mg.

The primary aim of the study will be pain relief after sevoflurane therapy. Pain intensity will be measured by NRS at 1-hour intervals (excluding sleep); decrease of 2 point for at least 4 hours will be considered significant. Secondary aim will be healing of ulcers. The effect will be controlled by elimination of pathologic microbial colonization, cleaning of the base of the wound and decreasing the size of the ulcer. Microbial colonization will be measured by microbial swab culture before application, after the 1st application before dressing and on the 5th day after application), the appearance of the defect base will be assessed by the appearance of the surface, the size of the defect will be measured in cm2.

02

Conditions studied

  • Leg Ulcer

Keywords

  • Leg Ulcer
  • Sevoflurane
  • Pain
  • Healing ulcer
  • Microbial colonization
03

In context

Leg Ulcer

174 studies on the registry are indexed under Leg Ulcer; 33 are open to participants now.

This study's planned enrollment of 50 is close to the median of 52 across 136 interventional studies indexed under Leg Ulcer.

Browse Leg Ulcer studies →

Lead sponsor

Charles University, Czech Republic is the lead sponsor of 228 studies on the registry; 76 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Patients with painful (pain intensity on the numerical scale NRS 0-10 is NRS>4) non- healing tibial venous ulcers

Exclusion criteria

Exclusion Criteria:

  • Allergy to sevoflurane
  • Inability to understand the pain-intensity questionnaire
05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Participant)
Enrollment
50 participants (estimated)

Study arms

  • Experimental
    Topical sevoflurane

    The active treatment group will have sevoflurane applied at approximately 1 ml/cm2 at the start of wound treatment,

    Drug: Sevoflurane

  • Active comparator
    Cyteal

    the control group will only have a standard rinse solution with Cyteal PIERRE FABRE MEDICAMENT, France (100 ml of skin fluid contains hexamidine diisetione 100 mg, chlorohexidine digluconate (solutio 20 %) 100 mg and chlorocresol 300 mg), with sevoflurane used to soak the absorbent material held under the distal pole of the wound.

    Combination Product: Cyteal

Interventions

  • Topical application of 1 mL sevoflurane per 1 cm2 ulcer area once or two times daily.

    Also known as: Sevorane

  • Combination productCyteal

    Rinsing and cleaning of ulcer.

06

What researchers measure

Primary outcomes

  1. Pain intensity

    Pain intensity measured by numeric rating scale (NRS) from 0 - no pain (the best result) to 10 - the worst possible pain using a standard questionnaire

    Time frame: Continuously for 5 days

Secondary outcomes

  1. Microbial colonization

    Microbial smear for culture

    Time frame: Before application of treatment, after the 1st application before tibial coverage and on the 5th day after application

  2. Size of skin defect

    Measured in cm2

    Time frame: 5 days

  3. Appearance of the ulcer bed

    Epithelial tissue, granulation tissue, slough, necrotic tissue

    Time frame: 5 days

07

Study locations

1 of 1 sites recruiting
  • Faculty Hospital Kralovske Vinohrady
    Prague, 100 00, Czechia
    Recruiting
    • Jiri Malek, M.D. · Contact
    • Spyridon Gkalpakiotis, M.D. · Sub investigator
    • Alice Kurzova, M.D. · Sub investigator
08

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it moved

Started May 2022 (actual). Primary completion is estimated for Oct 2027, 65 months after the start.

Since we started tracking on Sep 25, 2026, the dates moved once, on Oct 27, 2026: primary completion Apr 2026 → Oct 2027 and completion Jan 2027 → Jan 2028.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 27, 2022
First posted
Mar 31, 2022
StartActual
May 2, 2022
Primary completionEst.
Oct 30, 2027was Apr 2026
CompletionEst.
Jan 31, 2028was Jan 2027
Last update
Oct 27, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Sites
1 site added, 1 site removed
Show site
  • Faculty Hospital Kralovske Vinohrady · Prague, Czechia
Show 1 removed
  • Faculty Hospital Kralovske Vinohrady · Praha, Czechia
Oct 27, 2026
Primary completion
Apr 30, 2026→Oct 30, 2027
Oct 27, 2026
Study completion
Jan 31, 2027→Jan 31, 2028
Oct 27, 2026
Show all 1 update
  1. Oct 27, 2026
    1 site added, 1 site removed
    Show site
    • Faculty Hospital Kralovske Vinohrady · Prague, Czechia
    Show 1 removed
    • Faculty Hospital Kralovske Vinohrady · Praha, Czechia
    Primary completion Apr 30, 2026→Oct 30, 2027
    Study completion Jan 31, 2027→Jan 31, 2028
    + 2 other changes: index terms and verification date

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

09

Registry details

Key details

Study ID
NCT05303805
Collaborators
Faculty Hospital Kralovske Vinohrady
Responsible party
Jiri Malek (Assoc. Prof. Jiri Malek, MD, Ph.D., Charles University, Czech Republic) — Principal investigator
First posted
Mar 31, 2022
Start date
May 2, 2022
Primary completion
Oct 30, 2027 (estimated)
Completion
Jan 31, 2028 (estimated)
Last update
Oct 27, 2026

Study contacts

Jiri Malek, M.D.
Contact
malekj@fnkv.cz
+4202671622461
Jiri Malek, M.D.
Contact
malekj@fnkv.cz
+4202671622272461
Jiří Málek, M.D.
principal investigator · 3rd Medical Faculty of Charles University

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Sevoflurane

Start the discussion